Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Leber congenital amaurosis (LCA) is the earliest and most severe form of inherited retinal dystrophy, presenting in infancy with profound vision loss, nystagmus, and extinguished electroretinogram (ERG). The photoreceptor guanylate cyclase gene GUCY2D (HGNC:4689) encodes retinal guanylate cyclase 1 (RetGC1), a key enzyme in phototransduction. Biallelic pathogenic variants in GUCY2D underlie LCA type 1 (LCA1), accounting for 6–21% of cases (PMID:8944027).
GUCY2D‐related LCA follows an autosomal recessive inheritance pattern. Across multiple cohorts, at least 23 unrelated probands harbor biallelic GUCY2D variants, including homozygous and compound heterozygous changes in 15 families (PMID:11035546; PMID:27475985). Segregation analysis in a large Bedouin kindred demonstrated cosegregation of a novel missense variant c.2129C>T (p.Ala710Val) with disease in eight affected relatives (PMID:27475985). Case reports further document compound heterozygous splice site (c.2113+2_2113+3insT) and missense (c.2302C>T (p.Arg768Trp)) mutations in Japanese twins with classic LCA features (PMID:26097748).
To date, over 100 GUCY2D variants have been reported in LCA1, including missense (e.g., c.2302C>T (p.Arg768Trp)), nonsense, frameshift, and splicing mutations. The c.2302C>T (p.Arg768Trp) variant is recurrent in diverse populations, supporting its pathogenicity. Phenotypically, affected individuals exhibit early-onset severe visual impairment, nystagmus (HP:0000639), photophobia (HP:0000613), and high hypermetropia (HP:0000540), with fundus examination showing preserved photoreceptors in the macula despite functional loss (PMID:12623820).
Biochemical assays of RetGC1 mutant proteins reveal complete loss of cGMP synthesis for catalytic‐domain mutants and aberrant regulation by Ca2+‐sensor GCAPs for dimerization‐domain variants (PMID:11328726; PMID:11115851). Knockout and double‐knockout mouse models lacking RetGC1 demonstrate absence of cone ERG responses and progressive photoreceptor degeneration, both rescued by AAV‐mediated expression of wild‐type GUCY2D, confirming RetGC1’s essential role and therapeutic targetability (PMID:20593011).
The accumulation of genetic and functional data establishes a Strong gene–disease association for GUCY2D and LCA1. Genetic evidence includes ≥23 probands across 15 families with segregation and concordant clinical findings. Functional studies demonstrate loss‐of‐function or misregulation of RetGC1 consistent with photoreceptor pathology. These data support ongoing and future gene‐augmentation trials targeting GUCY2D in LCA1. Key take‐home: early genetic diagnosis of GUCY2D‐associated LCA enables prognostic counseling and enrollment in emerging gene therapies.
Gene–Disease AssociationStrong≥23 unrelated probands in 15 families; multi-family segregation; concordant histopathology and ERG loss Genetic EvidenceStrong23 probands, 8 affected relatives with segregation; compound heterozygotes and homozygotes across diverse cohorts Functional EvidenceModerateBiochemical assays and animal models demonstrate loss of RetGC1 activity and rescue by gene therapy |